These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

185 related items for PubMed ID: 18454990

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Alemtuzumab induction in deceased donor kidney transplantation.
    Shin M, Song SH, Kim JM, Kwon CH, Joh JW, Lee SK, Kim SJ.
    Transplant Proc; 2011; 43(6):2365-78. PubMed ID: 21839271
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Alemtuzumab induction therapy in highly sensitized kidney transplant recipients.
    Lü TM, Yang SL, Wu WZ, Tan JM.
    Chin Med J (Engl); 2011 Mar; 124(5):664-8. PubMed ID: 21518554
    [Abstract] [Full Text] [Related]

  • 8. Alemtuzumab versus interleukin-2 receptor antibodies induction in living donor kidney transplantation.
    Sampaio MS, Kadiyala A, Gill J, Bunnapradist S.
    Transplantation; 2009 Oct 15; 88(7):904-10. PubMed ID: 19935462
    [Abstract] [Full Text] [Related]

  • 9. Pilot study of rapid steroid elimination with alemtuzumab induction therapy in kidney and pancreas transplantation.
    Sundberg AK, Roskopf JA, Hartmann EL, Farney AC, Rohr MS, Stratta RJ.
    Transplant Proc; 2005 Mar 15; 37(2):1294-6. PubMed ID: 15848701
    [Abstract] [Full Text] [Related]

  • 10. Steroid-free tacrolimus monotherapy after pretransplantation thymoglobulin or Campath and laparoscopy in living donor renal transplantation.
    Tan HP, Kaczorowski D, Basu A, McCauley J, Marcos A, Donaldson J, Unruh M, Randhawa P, Zeevi A, Shapiro R.
    Transplant Proc; 2005 Dec 15; 37(10):4235-40. PubMed ID: 16387087
    [Abstract] [Full Text] [Related]

  • 11. A randomized trial of alemtuzumab versus antithymocyte globulin induction in renal and pancreas transplantation.
    Farney AC, Doares W, Rogers J, Singh R, Hartmann E, Hart L, Ashcraft E, Reeves-Daniels A, Gautreaux M, Iskandar SS, Moore P, Adams PL, Stratta RJ.
    Transplantation; 2009 Sep 27; 88(6):810-9. PubMed ID: 19920781
    [Abstract] [Full Text] [Related]

  • 12. A randomized trial of alemtuzumab vs. anti-thymocyte globulin induction in renal and pancreas transplantation.
    Farney A, Sundberg A, Moore P, Hartmann E, Rogers J, Doares W, Jarrett A, Adams P, Stratta R.
    Clin Transplant; 2008 Sep 27; 22(1):41-9. PubMed ID: 18217904
    [Abstract] [Full Text] [Related]

  • 13. Reversal of acute cellular rejection after renal transplantation with Campath-1H.
    Basu A, Ramkumar M, Tan HP, Khan A, McCauley J, Marcos A, Fung JJ, Starzl TE, Shapiro R.
    Transplant Proc; 2005 Mar 27; 37(2):923-6. PubMed ID: 15848576
    [Abstract] [Full Text] [Related]

  • 14. Campath-1H in renal transplantation: The University of Wisconsin experience.
    Knechtle SJ, Fernandez LA, Pirsch JD, Becker BN, Chin LT, Becker YT, Odorico JS, D'alessandro AM, Sollinger HW.
    Surgery; 2004 Oct 27; 136(4):754-60. PubMed ID: 15467659
    [Abstract] [Full Text] [Related]

  • 15. Kidney transplantation achievements in Mongolia.
    Jambaljav L, Nyamsuren D, Byambadash B, Ganbold L.
    Transplant Proc; 2010 Apr 27; 42(3):791-2. PubMed ID: 20430173
    [Abstract] [Full Text] [Related]

  • 16. Preliminary experience with alemtuzumab induction therapy combined with maintenance low-dose tacrolimus monotherapy in small-bowel transplantation in China.
    Yuan-Xin L, Ning L, You-Sheng L, Xiao-Dong N, Ming L, Jian W, Jie-Shou L.
    Transplant Proc; 2010 Apr 27; 42(1):29-34. PubMed ID: 20172275
    [Abstract] [Full Text] [Related]

  • 17. Alemtuzumab preconditioning allows steroid-calcineurin inhibitor-free regimen in live-donor kidney transplant.
    Refaie AF, Mahmoud KM, Ismail AM, Sheashaa HA, Kamal AI, Ghoneim MA.
    Exp Clin Transplant; 2011 Oct 27; 9(5):295-301. PubMed ID: 21967254
    [Abstract] [Full Text] [Related]

  • 18. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.
    Barth RN, Janus CA, Lillesand CA, Radke NA, Pirsch JD, Becker BN, Fernandez LA, Thomas Chin L, Becker YT, Odorico JS, D'Alessandro AM, Sollinger HW, Knechtle SJ.
    Transpl Int; 2006 Nov 27; 19(11):885-92. PubMed ID: 17018123
    [Abstract] [Full Text] [Related]

  • 19. Use of alemtuzumab (Campath-1H) as induction therapy in pediatric kidney transplantation.
    Ona ET, Danguilan RA, Africa J, Cabanayan-Casasola CB, Antonio ZL, Gutierrez-Marbella MA, dela Cruz R, Bumanglag N, Espedilla ME.
    Transplant Proc; 2008 Sep 27; 40(7):2226-9. PubMed ID: 18790199
    [Abstract] [Full Text] [Related]

  • 20. Alemtuzumab (Campath 1H) induction with tacrolimus monotherapy is safe for high immunological risk renal transplantation.
    Thomas PG, Woodside KJ, Lappin JA, Vaidya S, Rajaraman S, Gugliuzza KK.
    Transplantation; 2007 Jun 15; 83(11):1509-12. PubMed ID: 17565326
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.